Aspirin for Secondary Prevention of Atherosclerosis—Evidence or Dogma?
Author:
- 1 February 2025
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 10 (2) , 114
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female PatientsJAMA Cardiology, 2024
- Aspirin Monotherapy vs No Antiplatelet Therapy in Stable Patients With Coronary Stents Undergoing Low-to-Intermediate Risk Noncardiac SurgeryJACC, 2024
- Aspirin Use to Prevent Cardiovascular DiseaseJAMA, 2022
- The rise and fall of aspirin in the primary prevention of cardiovascular diseaseThe Lancet, 2019
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trialThe Lancet, 2000
- Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectorisThe Lancet, 1992
- The Cardiac Arrhythmia Suppression Trial (CAST)New England Journal of Medicine, 1989
- Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable AnginaNew England Journal of Medicine, 1983
- A Randomized, Controlled Trial of Aspirin in Persons Recovered From Myocardial InfarctionJAMA, 1980